<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005856</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02336</org_study_id>
    <secondary_id>9902</secondary_id>
    <secondary_id>U01CA062475</secondary_id>
    <secondary_id>CDR0000067883</secondary_id>
    <nct_id>NCT00005856</nct_id>
  </id_info>
  <brief_title>Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of oxaliplatin in treating&#xD;
      patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as&#xD;
      oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of oxaliplatin in patients with newly diagnosed&#xD;
      glioblastoma multiforme who are receiving or not receiving anticonvulsants known to be&#xD;
      metabolized by P450.&#xD;
&#xD;
      II. Determine the dose-limiting toxicity and safety profile of this drug in this patient&#xD;
      population.&#xD;
&#xD;
      III. Assess the pharmacokinetics of this drug on this schedule and determine the effects of&#xD;
      P450-inducing anticonvulsants on the pharmacokinetics in these patients.&#xD;
&#xD;
      IV. Determine the radiographic response rate in patients treated with this drug.&#xD;
&#xD;
      V. Determine survival and drug toxicity in these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study of oxaliplatin followed by a phase II study.&#xD;
      Patients are stratified according to whether concurrent anticonvulsant drugs induce P450 (yes&#xD;
      vs modest/no or no drugs).&#xD;
&#xD;
      Phase I: Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14&#xD;
      days for a maximum of 6 courses in the absence of unacceptable toxicity or disease&#xD;
      progression.&#xD;
&#xD;
      Cohorts of 3-6 patients (per stratum) receive escalating doses of oxaliplatin until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Phase II: Patients receive oxaliplatin as in phase I at the MTD determined in phase I.&#xD;
&#xD;
      Patients are followed at 1 month, every 2 months until disease progression, and then monthly&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 24 patients (12 per stratum) will be accrued for the phase I&#xD;
      part of this study within 8-12 months. A total of 18-35 patients will be accrued for the&#xD;
      phase II part of this study within 5-12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>December 2000</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) defined as the dose level at which 2 out of 6 or the dose level below that at which &gt;= 2 of 3 or &gt; 2 of 6 patients experience dose-limiting toxicity (DLT) assessed by Common Toxicity Criteria (CTC) version 2.0 (Phase I)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DLT is defined as grade 3 or 4 nonhematological toxicities or hematological toxicities as assessed by CTC version 2.0 (Phase I)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of oxaliplatin (Phase I)</measure>
    <time_frame>At baseline, at immediately post infusion, at 2, 4, 22, and 24 hours (of course 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (Phase II)</measure>
    <time_frame>Up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of survival (Phase II)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Estimated with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicity as assessed by CTC version 2.0 (Phase II)</measure>
    <time_frame>Up to 7 years after completion of study treatment</time_frame>
    <description>The proportion of patients with serious or life threatening toxicities will be estimated along with 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (oxaliplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oxaliplatin)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (oxaliplatin)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed supratentorial grade IV astrocytoma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
          -  Subtotal resection or biopsy with measurable and contrast-enhancing disease on the&#xD;
             postoperative, pretreatment MRI/CT scan&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serious concurrent infection or medical illness that would jeopardize ability to&#xD;
             receive protocol chemotherapy with reasonable safety&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except curatively treated carcinoma&#xD;
             in situ or basal cell skin cancer&#xD;
&#xD;
          -  No grade 2 or greater pre-existing sensory neuropathy&#xD;
&#xD;
          -  No history of allergy to platinum compounds or to antiemetics appropriate for&#xD;
             administration in conjunction with protocol chemotherapy&#xD;
&#xD;
          -  Mini mental score at least 15&#xD;
&#xD;
          -  No prior immunotherapy for glioblastoma multiforme&#xD;
&#xD;
          -  No prior biologic therapy for glioblastoma multiforme, including:&#xD;
&#xD;
               -  Immunotoxins&#xD;
&#xD;
               -  Immunoconjugates&#xD;
&#xD;
               -  Antiangiogenesis compounds&#xD;
&#xD;
               -  Antisense&#xD;
&#xD;
               -  Peptide receptor antagonists&#xD;
&#xD;
               -  Interferons&#xD;
&#xD;
               -  Interleukins&#xD;
&#xD;
               -  Tumor infiltrating lymphocytes&#xD;
&#xD;
               -  Lymphokine activated killer cells&#xD;
&#xD;
               -  Gene therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
          -  No prior chemotherapy for glioblastoma multiforme&#xD;
&#xD;
          -  No prior hormonal therapy for glioblastoma multiforme&#xD;
&#xD;
          -  Prior glucocorticoid therapy for glioblastoma multiforme allowed&#xD;
&#xD;
          -  Must be maintained on a stable (lowest required dose) corticosteroid regimen for at&#xD;
             least 5 days before and during study&#xD;
&#xD;
          -  No concurrent dexamethasone as an antiemetic&#xD;
&#xD;
          -  No prior radiotherapy for glioblastoma multiforme&#xD;
&#xD;
          -  Recovered from immediate postoperative period&#xD;
&#xD;
          -  At least 10 days since prior anticonvulsant drug that induces hepatic metabolic&#xD;
             enzymes&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy Batchelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Approaches to Brain Tumor Therapy Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Approaches to Brain Tumor Therapy Consortium</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

